MabGenesis Inc. IPO: Date, Status and What We Know
IPO facts
- Status
- Approved
- Market
- Japan
- Country
- Japan
- Exchange
- Tokyo Stock Exchange Growth Market
- Ticker
- 653A
- Sector
- Pharmaceuticals (veterinary antibody drugs)
- Expected timing
- Listing planned for 2 November 2026, according to the Tokyo Stock Exchange outline of 28 September 2026
- Book-building
- –
- Pricing date
- First trading day
- Price range
- Not announced
- Offering size
- 1,987,900 shares
- Last valuation
- Not announced
About MabGenesis Inc.
MabGenesis, based in Yokohama, researches and develops antibody drugs for pets.
IPO notes
The Tokyo Stock Exchange approved the listing of MabGenesis shares on its Growth Market on 28 September 2026, with listing planned for 2 November 2026 (jpx.co.jp, company outline of 28 September 2026). The outline sets the indicated price range for 13 October, book-building for 15 to 21 October, pricing for 22 October and applications for 23 to 28 October; no price range had been published as of 5 October 2026. The planned offering is 940,700 new shares and 1,047,200 shares offered by selling shareholders, plus an over-allotment of up to 298,000 shares, with Tokai Tokyo Securities as lead manager.
Other IPOs in this market
Sources
- jpx.co.jp · New listing company outline (TSE Listing Department, 28 Sep 2026): listing date, offering terms, timetable ·
- jpx.co.jp · New Listings table (updated 5 Oct 2026) ·
Named as plain text with what each source states and the date it was checked.